Search results
Results from the WOW.Com Content Network
[6] [6] Peak concentrations of phentermine are reached 6 hours following oral administration of a dose of 15 mg. [6] The steady-state levels of phentermine with continuous administration have been found to be around 200 ng/mL in clinical studies. [6] The oral bioavailability of phentermine is not affected by intake of a high-fat meal. [6]
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market.
Fenfluramine as a single drug was first introduced in the 1970s, but was not popular because it only temporarily reduced weight. [1] A 1984 study found a weight loss of 7.5 kg on average in 24 weeks, as compared to 4.4 kg under placebo. [4] It sold modestly until the 1990s, when it was combined with phentermine and heavily marketed. [1]
Influenza is surging in the U.S., with doctor visits for flu symptoms at a 15-year high. Why is this flu season so bad? Doctors discuss flu trends and prevention.
On the CDC website Friday, webpages with detailed information for doctors working with HIV patients were not accessible. The link for the site tilted: “HIV Nexus: CDC Resources for Clinicians ...
For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...
If something is wrong with your mobile web browser, it can cause AOL websites to stop working. Get back to what you're doing by fixing the source of the problem. Try each step in order, then check to see if the issue is resolved before moving on. 1. Check if your device is connected to a network. 2. Update your browser to the latest version. 3.
Phentermine and topiramate was developed by Vivus, a California pharmaceutical company. In December 2009, Vivus, Inc. submitted a new drug application (NDA) to the FDA and on 1 March 2010, Vivus, Inc. announced that the FDA accepted the NDA for review.